Ultimovacs ASA (ULTIO.OL)
| Previous Close | 76.80 |
| Open | 72.00 |
| Bid | 69.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 72.00 - 72.00 |
| 52 Week Range | 72.00 - 72.00 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy
Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 yearsUV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint inhibition Oslo, 25 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of long-term follow-up data on UV1 in the Journal for ImmunoTherapy of Cancer (JITC). The data show that dynamic UV1 specific immune r
- GlobeNewswire
Ultimovacs ASA: First quarter 2022 result presentation
Oslo, 12 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its first quarter 2022 results today. The presentation by the company's management team can be followed as a live webcast at 13:00 CET and will be made available on the website. It will be possible to post questions during the presentation through the webcast. Highlights for the first quarter of 2022: On 22 April 2022, Ultimovacs received a Notice of Allowance
- GlobeNewswire
Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting
UV1 immune monitoring data from three Phase I/IIa clinical trials show dynamic T cell responses lasting up to 7.5 yearsMeasurable UV1-specific immune response in 91% of patients when combined with checkpoint inhibitor, as compared to 82% and 67% without checkpoint inhibitorImmune responses induced more rapidly when UV1 was combined with a checkpoint inhibitorDevelopment of UV1-specific immune responses associated with longer survival time Oslo, 10 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULT
